Related references
Note: Only part of the references are listed.Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort
Neal E. Ready et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Antibody Opsonization of a TLR9 Agonist-Containing Virus-like Particle Enhances In Situ Immunization
Caitlin D. Lemke-Miltner et al.
JOURNAL OF IMMUNOLOGY (2020)
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Alex D. Waldman et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
Debarati Banik et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
Jennifer N. Brudno et al.
BLOOD REVIEWS (2019)
Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial
Ulrich Keilholz et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer
Raghav Sundar et al.
BMC CANCER (2018)
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara et al.
LANCET (2018)
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
Seung Tae Kim et al.
NATURE MEDICINE (2018)
Immunotherapies: Exploiting the Immune System for Cancer Treatment
Jeffrey Koury et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2018)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs et al.
JAMA ONCOLOGY (2018)
Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
Y. -J. Bang et al.
ANNALS OF ONCOLOGY (2018)
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
Yelena Y. Janjigian et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases
Krupa Naran et al.
FRONTIERS IN MICROBIOLOGY (2018)
Next generation predictive biomarkers for immune checkpoint inhibition
Yulian Khagi et al.
CANCER AND METASTASIS REVIEWS (2017)
Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape
Malte Mohme et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET (2017)
Prognostic significance of PD-L1 in solid tumor An updated meta-analysis
Qianqian Wang et al.
MEDICINE (2017)
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott et al.
NATURE (2017)
Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer
Yung-Jue Bang et al.
CLINICAL CANCER RESEARCH (2017)
Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications
Cinzia Solinas et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Phase Ib/II study of elisidepsin in metastatic or advanced gastroesophageal cancer (IMAGE trial)
Russell Petty et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Strategies to genetically engineer T cells for cancer immunotherapy
Timothy T. Spear et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Additional Support for the Introduction of Immune Cell Quantification in Colorectal Cancer Classification
Robert L. Ferris et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Kei Muro et al.
LANCET ONCOLOGY (2016)
Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
Michael B. Bernstein et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Additional Support for the Introduction of Immune Cell Quantification in Colorectal Cancer Classification
Robert L. Ferris et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside
Qi Zhang et al.
ONCOIMMUNOLOGY (2016)
ErbB-targeted CAR T-cell immunotherapy of cancer
Lynsey M. Whilding et al.
IMMUNOTHERAPY (2015)
Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab
Giovanna Scapin et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Marie Vetizou et al.
SCIENCE (2015)
Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab
Giovanna Scapin et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2015)
Vascular Endothelial Growth Factor A Inhibition in Gastric Cancer
Do Joong Park et al.
GASTRIC CANCER (2015)
Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial
Ryan D. Guest et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Phase I clinical trial of vaccination with LY6K-derived peptide in patients with advanced gastric cancer
Hajime Ishikawa et al.
GASTRIC CANCER (2014)
Cancer CARtography: charting out a new approach to cancer immunotherapy
Jaina M. Patel et al.
IMMUNOTHERAPY (2014)
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice
Liufu Deng et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours
Jerome Galon et al.
JOURNAL OF PATHOLOGY (2014)
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke et al.
LANCET ONCOLOGY (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Prediction of Cancer Incidence and Mortality in Korea, 2014
Kyu-Won Jung et al.
CANCER RESEARCH AND TREATMENT (2014)
Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
Chad Tang et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges
Ethan Q. Han et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
Li Shi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Innate and adaptive immune cells in the tumor microenvironment
Thomas F. Gajewski et al.
NATURE IMMUNOLOGY (2013)
Molecular mechanisms of T cell co-stimulation and co-inhibition
Lieping Chen et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer
Toru Masuzawa et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
The immune contexture in human tumours: impact on clinical outcome
Wolf Herman Fridman et al.
NATURE REVIEWS CANCER (2012)
Cancer immunotherapy comes of age
Ira Mellman et al.
NATURE (2011)
Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma
Christy Ralph et al.
CLINICAL CANCER RESEARCH (2010)
Evaluations of Interferon-γ/Interleukin-4 Ratio and Neutrophil/Lymphocyte Ratio as Prognostic Indicators in Gastric Cancer Patients
Hideyuki Ubukata et al.
JOURNAL OF SURGICAL ONCOLOGY (2010)
G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy
A. D. Gilliam et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1
Hidenobu Ishizaki et al.
CLINICAL CANCER RESEARCH (2006)
An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: The GC4 study
JA Ajani et al.
CANCER (2006)
Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2
S Wada et al.
CANCER RESEARCH (2005)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
Current developments in cancer vaccines and cellular immunotherapy
A Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Fighting infection using immunomodulatory agents
KN Masihi
EXPERT OPINION ON BIOLOGICAL THERAPY (2001)
Share Paper
